News

N8 MEDICAL ANNOUNCES LICENSING TRANSACTION IN UROLOGY MARKET

COLUMBUS, OH – N8 Medical, Inc., an emerging biomedical technology company focused on developing novel, proprietary antimicrobial coatings for medical devices and pharmaceuticals, is very pleased to announce that it is entered into a license agreement in the field of urology for application of its CSA technology. Under the terms of the license, N8 Medical has granted exclusive rights for the development and commercialization of urinary catheters, urological stents and other urological medical devices in the United States, Canada, Central and South America and Africa. N8 Medical retains rights to those devices in the European Union, Japan, China, India, the Middle East and rest of world.

N8 MEDICAL ENGAGES DIRECTOR OF SAFETY AND TOXICOLOGY PROGRAMS

COLUMBUS, OH – N8 Medical, Inc., an emerging biomedical technology company focused on developing novel, proprietary antimicrobial additives for consumer products, antimicrobial coatings for medical devices and pharmaceuticals, is very pleased to announce that Dr. Jim Joly, through his relationship with Pharma-GPS, LLC, has agreed to join N8 Medical as Director of Toxicology, effective January 1, 2013.

N8 MEDICAL HIRES INDUSTRY LEADER AS CHIEF OPERATING OFFICER

COLUMBUS, OH – N8 Medical, Inc., an emerging biomedical technology company focused on developing novel, proprietary antimicrobial coatings for medical devices and pharmaceuticals, is very pleased to announce that Michael Triplett, Ph.D. has agreed to join N8 Medical as Chief Operating Officer, effective October 8th, 2012.

N8 COMPOUNDS IN ORTHOPEDIC IMPLANT COATING COMPLETELY PREVENT MRSA INFECTIONS

COLUMBUS, OH – October 2, 2012 – N8 Medical today announced that research published in the November issue of the Journal of Biomaterials has shown that a coating based on N8 Medical’s proprietary antimicrobial compound CSA-13 was able to completely prevent infection in a sheep model. In contrast, all of the control animals that were similarly challenged with a MRSA biofilm developed severe infections, most requiring euthanization prior to the conclusion of the 12-week study. CSA-13 is a member of the class of CSA compounds that have been shown to have broad spectrum antimicrobial properties that mimic those of naturally occurring antimicrobial peptides that form part of the human body’s innate immune system. The university based study was funded by a grant from the National Institutes of Health.

PUBLISHED RESULTS: N8 MEDICAL'S ANTIMICROBIAL COMPOUNDS DO NOT ENGENDER MUTATIONAL RESISTANCE

COLUMBUS, OH – August 21, 2012 – N8 Medical, Inc. (N8), an emerging company that focuses on novel antimicrobial coatings and antibiotic pharmaceutical products to prevent and treat hospital acquired infections, announced the electronic publication of a peer reviewed article entitled “In vitro evaluation of the potential for resistance to ceragenin CSA-13” in the Journal of Antimicrobial Chemotherapy. The authors, led by Dr. Paul B. Savage of Brigham Young University (Provo, UT) studied the effects of multiple exposures of sub-lethal doses of bacterial pathogens to several commonly used antibiotics along with CSA-13 to ascertain whether the bacteria were able to develop mutational resistance. One of the major healthcare concerns is the rising number of multidrug resistant bacteria that are no longer susceptible to available antibiotic therapy.

N8 MEDICAL INC. ANNOUNCES SIGNIFICANT LICENSING TRANSACTION FOR ITS ANTIMICROBIAL TECHNOLOGY

COLUMBUS, OH – August 6, 2012 – N8 Medical, Inc. (N8), an emerging company focused on novel antimicrobial coatings and pharmaceutical products based upon proprietary compounds, announced the completion of a significant transaction involving the sale of certain pharmaceutical uses that also resulted in liquidity for its investor group. N8, backed by Columbus, Ohio-based private equity firm Empire Advisors, LLC, holds a worldwide, exclusive license to proprietary CSA based technologies for medical device coatings and certain pharmaceutical applications. The risk of hospital-acquired infection is one the greatest concerns in the medical field and is expected to add more than $30 billion a year to healthcare costs.

N8 MEDICAL INC. AND HYDROMER INC. ENTER INTO A STRATEGIC DEVELOPMENT AGREEMENT

COLUMBUS, OH – July 31, 2012 – Hydromer, Inc. (HYDI.PK) and N8 Medical, Inc. (private equity-backed company) have entered into a Supply and Support Agreement. Under the terms of this agreement, both parties will work together to jointly create and commercialize new antimicrobial coatings for the medical device market. By capitalizing on Hydromer’s leadership in medical grade polymeric coating technology, and combining N8’s novel class of compounds known as Ceragenins (CSA-13) which are patented synthetic peptidomimetic compounds invented by Dr. Paul B. Savage at Brigham Young University that mimic the polyfunctional and broad spectrum activity of a key component of the human innate immune system, the companies are making available a new technology to combat hospital acquired infections (HAI’s).

N8 MEDICAL TEAMS WITH MEDICAL CAPITAL ADVISORS AFTER SUCCESSFUL ORTHOPEDIC TESTING

Dublin, OH – April 6, 2012 – N8 Medical announced that it has engaged Medical Capital Advisors (MedCap) to represent N8 Medical and assist with licensing efforts in the orthopedics industry. MedCap Advisors provides specialized, sophisticated business consulting and M&A guidance exclusively to the medical technology and healthcare sectors. Highly successful orthopedic testing results of certain CSA compounds licensed by N8 from Brigham Young University were recently presented at the annual conference for the American Academy of Orthopedic Surgeons. Working under an NIH grant, researchers from the University of Utah presented results from large animal studies where CSA coated implants showed outstanding efficacy in preventing infections. N8 has made these impressive results available under NDA to various orthopedic companies.

N8 MEDICAL ANNOUNCES EQUITY CAPITAL RAISE

Columbus, OH – March 7, 2011 /PRNewswire-FirstCall/ – N8 Medical, Inc., a leading developer of antimicrobial peptide mimics focused on reducing or eliminating certain hospital acquired infections, announced today that it completed its initial equity raise. N8 expects to use the proceeds from the financing for its licensing and development activities as well as for the development and commercialization of its own antimicrobial products and devices. The company stated that the financing is expected to be sufficient to fund all planned company activities well into and potentially through 2013, including its programs in dermatology, orthopedics and development of enhanced coating technologies for medical devices.

“We are extremely pleased to have financed our operations through the foreseeable future, including planned development activities to support our licensing efforts and the regulatory clearance of our initial antimicrobial medical device. We have assembled an outstanding management team and advisory board, as well as an esteemed group of scientific experts,” commented David J. Richards, Chief Executive Officer of N8 Medical. “We have already made considerable progress and look forward to both completing additional license agreements and furthering our development goals. This funding also satisfies our projected needs of taking the first device through regulatory clearance.”

N8 MEDICAL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD

Leading experts in the fields of infectious disease, respiratory medicine and antimicrobial medical
devices agree to join the N8 Medical SAB.

Columbus, OH – February 14, 2011 – N8 Medical Inc., an emerging biomedical technology company focused on the development of antimicrobial peptide mimics for many fields of application, including the prevention and treatment of hospital acquired infections, announced today that Richard Gallo, M.D., Ph.D., Tomas Ganz, M.D., Ph.D., Professor Sean P. Gorman, CBE, Ph.D., FPSNI, and Michael S. Niederman, M.D., have all agreed to serve as members of its Scientific Advisory Board (SAB).

“We are both pleased and honored that the world’s leading experts in the fields of antimicrobial peptides, innate immunity, respiratory infections and antimicrobial medical devices have agreed to join our SAB” commented David J. Richards, Chief Executive Officer of N8 Medical. “We believe that their guidance and input will help us maximize the potential of our technology’s promise in significantly reducing the morbidity and mortality associated with hospital acquired infections.”

N8 MEDICAL OBTAINS EXCLUSIVE LICENSE FROM BRIGHAM YOUNG UNIVERSITY

Novel technology has potential to provide unprecedented protection against hospital-acquired infections

Columbus, OH – October 14, 2010 – N8 Medical Inc., an emerging biomedical technology company, has entered into a license agreement with Brigham Young University for a patented class of compounds known as ceragenins, giving it exclusive worldwide rights to the technology for pharmaceutical and medical device applications excluding ophthalmology applications.

The license forms the basis of N8 Medical's program for the development of ceragenin technology to produce antimicrobial coatings for a wide variety of medical devices including urinary catheters, endotracheal tubes, hemodialysis catheters and orthopedic implants to help prevent hospital acquired infections (HAIs).